Instrument Inactif

Autres langues LARR HEALPAR

Actions

LSPR

US51724W1071

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Larkspur Acquisition Completes Merger With ZyVersa Therapeutics	13/12/22
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")	13/12/22
Larkspur Health Acquisition Corp.(NasdaqGM:LSPR) dropped from NASDAQ Composite Index	12/12/22
Larkspur Health Acquisition Corp. announced that it has received $8.635 million in funding	12/12/22
ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction.	12/12/22
LARKSPUR HEALTH ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	09/12/22
Larkspur Health Acquisition Corp. has Changed its Name to ZyVersa Therapeutics, Inc	09/12/22
ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit	22/11/22
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.	15/11/22
LARKSPUR HEALTH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	14/11/22
Larkspur Health Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference	28/10/22
Larkspur Health Acquisition Refiles Registration Statement for Business Combination Agreement With ZyVersa Therapeutics	27/09/22
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update	27/09/22
Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging	22/08/22
LARKSPUR HEALTH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	16/08/22
Larkspur Health Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics	15/08/22
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper	03/08/22
Larkspur Health Acquisition : ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp - Form 8-K	22/07/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues LARR HEALPAR

Actions

LSPR

US51724W1071

Autres langues

Filtres